In 2002, the Taisho Pharmaceutical Group established Taisho Toyama Pharmaceutical Co., Ltd. as a joint venture with Toyama Chemical Co., Ltd. The joint venture was set up as a sales company for prescription pharmaceuticals in Japan, with the aim of enhancing the Group’s ability to create new drugs in the prescription pharmaceutical business. This alliance enables Taisho Toyama Pharmaceutical to conduct marketing of both the new drugs launched by consolidated subsidiary Taisho Pharmaceutical as a result of its research and development (R&D) activities, and the new drugs created by Toyama Chemical.
Taisho Toyama Pharmaceutical has a product lineup centered on treatments in the fields of infectious diseases, inflammatory/immunologic diseases, and metabolic diseases. For details on individual products, please visit Taisho Toyama Pharmaceutical’s website.
See the “Main Products” of Taisho Toyama Pharmaceutical Co., Ltd.(Japanese site)
New Drug Research and Development
Taisho Pharmaceutical, which is advancing R&D for new drugs, has designated infectious diseases, orthopedic disorders, central nervous system (CNS) diseases and metabolic diseases as its priority fields R&D. By concentrating business resources in those priority fields, Taisho Pharmaceutical is working to quickly launch new products. In parallel, the company is striving to expand its new drug pipeline by promoting in-licensing of promising compounds from and joint R&D initiatives with companies and research institutions in Japan and overseas.
See Taisho Pharmaceutical Holdings’s “Development Status of Prescription Pharmaceuticals”